Type 2 & other diabetes

Proteomics profiling and association with cardiorenal complications in type 2 diabetes subtypes in Asian population

Diabetes Res Clin PractPublished Cohort study

Authors' conclusion

Each T2D subtype has unique proteomics signature and association with clinical outcomes and underlying mechanisms.

Study context

Population
Multi-ethnic Asians with T2D clustered in three subtypesSevere insulin-resistant diabetes with relative insulin insufficiency (SIRD-RII) 19%, MOD 45%, mild age-related diabetes with insulin insufficiency (MARD-II) 36%
Participants
645 participants
Exposure
Proteomic profiles across T2D subtypes SIRD-RII, MOD and MARD-II
Outcome
Subtype-specific proteomic biomarkers and their association with cardiorenal complications
Methodological detailsproteomics analysis, multi-ethnic Asian, 1448 plasma proteins at baseline, multivariable Cox regression
  • Proteomics analysis
  • Multi-ethnic Asian
  • 1448 plasma proteins at baseline
  • Multivariable Cox regression

Main finding

As reported in the abstract

Proteins differing across subtypes · baseline
Proteins with significantly different expression across subtypes
295

Observational data: associations, not effects.

Further findings

Protein associations with complications by subtype

SIRD-RII: ADH4, ACY1, THOP1, IGFBP2, NEFL, ENTPD2, CALB1, HAO1, CTSV, ITGAV, SCLY, EDA2R, ERBB2 associated with progressive CKD; LILRA5 with incident heart failure (HF)
MOD: TAFA5, RSPO3, EDA2R associated with incident HF
MARD-II: FABP4 associated with progressive CKD; PTPRN2 with MACE

Genetically determined proteins and kidney function

Genetically determined NEFL and CALB1 associated with kidney function decline

Original publication

Proteomics profiling and association with cardiorenal complications in type 2 diabetes subtypes in Asian population. Diabetes Res Clin Pract. Published 25 July 2024. doi:10.1016/j.diabres.2024.111790

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.